NCT06651970 2026-02-23Acalabrutinib Monotherapy vs Investigator's Choice of Treatment in Patients With CL Leukaemia and Heart FailureAstraZenecaPhase 4 Recruiting60 enrolled
NCT03328078 2025-06-05CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)Curis, Inc.Phase 1/2 Recruiting152 enrolled
NCT04104776 2025-05-15A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and LymphomasNovartisPhase 1/2 Recruiting275 enrolled
NCT04097067 2024-08-27ISRT 20 Gy for Indolent Localized Gastrointestinal (GI)-LymphomaUniversity Hospital MuensterPhase NA Recruiting83 enrolled
NCT04601584 2024-03-06GNR-084 Safety and Pharmacological Characteristics in Refractory or Relapse B-cell Precursor ALLAO GENERIUMPhase 1/2 Recruiting36 enrolled